TORECAN
LOE ApproachingNDARECTALSUPPOSITORY
Approved
Apr 1963
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 8h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TORECAN is a small-molecule suppository approved in 1963 for rectal administration. The exact indication and mechanism of action are not specified in available data. This is a legacy product with a well-established safety and efficacy profile.
LOE Approaching
As a legacy product approaching loss of exclusivity with moderate competitive pressure (30/100), the brand team is likely focused on managed decline and cost optimization rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
TORECAN offers limited career growth opportunity given its LOE-approaching status and zero linked job postings. Roles are typically focused on managed decline, cost containment, and compliance rather than market expansion or innovation.
Brand ManagerField Sales Representative
Worked on TORECAN at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.